NJII introduces immunotherapy training for biopharma companies

The New Jersey Innovation Institute has launched a training program for biopharmaceutical companies to study new immunotherapies, such as CAR-T cell therapy. Immunotherapy generally is a treatment in which cells in the human body are recoded and injected back into a patient in order to train the patient’s immune system to fight various diseases such as cancer. Cancer centers such as Hackensack Meridian Health’s John Theurer Cancer Center and Memorial Sloan Kettering, and pharmaceutical giants including Celgene and Johnson & Johnson have made big bets on the treatment.

Read full article on